• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
【24h】

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

机译：抑郁症门诊患者的单一异构体SSRI艾司西酞普兰固定剂量试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Escitalopram is the single isomer responsible for the serotonin reuptake inhibition produced by the racemic antidepressant citalopram. The present randomized, double-blind, placebo-controlled, fixed-dose multicenter trial was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of major depressive disorder. METHOD: Outpatients with an ongoing DSM-IV major depressive episode (N = 491) were randomly assigned to placebo, escitalopram, 10 mg/day, escitalopram, 20 mg/day, or citalopram, 40 mg/day, and entered an 8-week double-blind treatment period following a 1-week single-blind placebo lead-in. Clinical response was evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS), the 24-item Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions (CGI) scales, the Hamilton Rating Scale for Anxiety (HAM-A), and patient-rated quality-of-life scales. RESULTS: Escitalopram, at both doses, produced significant improvement at study endpoint relative to placebo on all measures of depression; significant separation of escitalopram from placebo was observed within I week of double-blind treatment. Citalopram treatment also significantly improved depressive symptomatology compared with placebo; however, escitalopram, 10 mg/day, was at least as effective as citalopram, 40 mg/day, at endpoint. Anxiety symptoms and quality of life were also significantly improved by escitalopram compared with placebo. The incidence of discontinuations due to adverse events for the escitalopram 10 mg/day group was not different from the placebo group (4.2% vs. 2.5%; p = .50), and not different for the escitalopram 20 mg/day group and the citalopram 40 mg/day group (10.4% vs. 8.8%; p = .83). CONCLUSION: Escitalopram, a single isomer SSRI, is well-tolerated and has demonstrated antidepressant efficacy at a dose of 10 mg/day.
机译：背景：艾司西酞普兰是一种单一的异构体，可抑制外消旋抗抑郁药西酞普兰产生的5-羟色胺再摄取。本随机，双盲，安慰剂对照，固定剂量的多中心试验旨在评估依西酞普兰在治疗重度抑郁症中的疗效和耐受性。方法：将正在进行DSM-IV重度抑郁发作（N = 491）的门诊患者随机分配至安慰剂，依他普仑10毫克/天，依他普仑20毫克/天或西酞普兰40毫克/天，并输入8- 1周单盲安慰剂导入后的1周双盲治疗期。临床反应通过蒙哥马利-阿斯伯格抑郁量表（MADRS），24项汉密尔顿抑郁量表（HAM-D），临床总体印象（CGI）量表，汉密尔顿焦虑量表（HAM-A）进行评估）以及患者评估的生活质量量表。结果：两种剂量的艾司西酞普兰在所有终点抑郁症方面均较安慰剂组产生了显着改善，相对于安慰剂而言。在双盲治疗的1周内观察到依他普仑与安慰剂的显着分离。与安慰剂相比，西酞普兰治疗还可以显着改善抑郁症状。然而，依西酞普兰（10 mg /天）在终点时至少与西酞普兰（40 mg /天）一样有效。与安慰剂相比，依他普仑可显着改善焦虑症状和生活质量。依他普仑10 mg /天组因不良事件而停药的发生率与安慰剂组无差异（4.2％vs. 2.5％; p = .50），依他普仑20 mg /天组与安慰剂组无差异。西酞普兰40 mg /天组（10.4％vs.8.8％; p = 0.83）。结论：艾司西酞普兰是一种单一的SSRI异构体，耐受性良好，在每天10 mg的剂量下已显示出抗抑郁功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号